| |
Integrating biology, chemistry, animal, and clinical studies
in house, the Company is aiming at building the first
novel drug discovery platform in China for fibrosis, cancer,
inflammation and viral infection diseases. This DNA-to-NDA
platform will significantly speed up the process from
gene to drugs at a fraction of the cost normally associated
with drug development in developed countries.
Armed with the vast knowledge pool generated from the
Human Genome Project, we focused on drugable genes such
as kinase, phosphatase, and protease. To elucidate their
function, more than 300 carefully selected potential target
genes have been systematically studied by analyzing protei-protein
interaction, gene expression profile in disease tissues,
protein function in disease-related signal transduction
pathways. These validated targets lay a solid foundation
for downstream drug development.
Through our technology platform, Shanghai Genomics
has discovered several new members of a tumor surface
antigen family (RLs), which can be specifically recognized
by immune killer cells (NK), and a group of new kinases
involved in cell cycle regulation. These genes can be
either used as diagnostic markers or high throughput screening
target. Compunds from both chemistry synthesis and Chinese
herb medicine are used to look for new kinase inhibitors.
To supplement biochemical screening, the Company has also
built a highly sensitive fluorescence-based cell model
for in vivo drug screening, which is characterized by
high speed, low dosage, high specificity, and more closely
resembling physiological conditions.
To generate new chemical entity, our chemistry group has
also designed new compounds for anti-inflammation, anti-fibrosis,
and anti-cancer applications. These compunds can be tested
in various biochemical, cellular, and animal models for
efficacy study. We also licese-in pre-clincal stage compounds
from other US-based biotech companies to take advantage
of our efficient pre-clinical and clinical studies in
China. Combing our chemistry synthesis power and our sophiticated
biology is the key to the Company’s future drug development
program.
Shanghai Genomics also seeks for rigorous IP protection
by filing both domestic and PCT patents on proprietary
drug lead or target discovered in the Company. This will
not only ensure the irreplaceable position of our products
in domestic market, but also pave the path for their entrance
into the global market.
|
|
|
